Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-064: Telisotuzumab Adizutecan in Refractory Metastatic Colorectal Cancer
NCT06614192Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Adverse Events up to 4 Years, Percentage of Participants with Clinically Significant Vital Sign Measurements up to 4 Years and 4 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06614192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614192.